Long Road to Legalization: Federal Council Finally Approves Cannabis Legislation

Berlin – Germany, 2024-03-22

Historic decision: The Cannabis Legalization Act was passed without a mediation committee

The German Federal Council (Bundesrat) approved the Cannabis Act in its session on March 22, 2024. Requests for convening the Mediation Committee did not receive a majority.


Legal possession and consumption of limited amounts

The law provides for a partial legalization of cannabis. It allows for the possession of up to 25 grams, up to 50 grams within one’s own four walls. Additionally, the cultivation of three cannabis plants in one’s own apartment becomes legal, with the harvested cannabis intended solely for personal use and not for distribution.


For more information, see the following Source:
Federal Council – 1042nd meeting on 22.03.2024

PR-Contact for Natural Pharma

Dr. Daniel König
+49 (0) 2173 940 95 91
press(ät)natpha.com

About Natural Pharma

Natural Pharma Resource (Natural Pharma) GmbH was founded at the beginning of 2022 and is based in Langenfeld, Germany.

The pharmaceutical and biotechnological company focuses on the import, storage, manufacturing, distribution and export of pharmaceutical products, preparations and substances, in particular medicinal products under the German Medicines Act (AMG), narcotics under the German Narcotics Act (BtMG) and cannabis for medicinal purposes as well as research and development in this field.

We are licensed pharmaceutical wholesalers according to § 52a of the German Medicines Act (AMG) and have a permit to handle narcotics according to § 3 of the Federal Institute for Drugs and Medical Devices (BtMG).

For more information, visit: Natural Pharma

Our Philosophie

The company philosophy of Natural Pharma is simple. The goal is to provide patients with high quality natural and medicinal products, especially those made from cannabis plants.
Natural Pharma Resource GmbH is committed to selecting manufacturers that take into account important patient welfare criteria in order to provide an additional therapeutic option for patients with previously unsatisfactory therapeutic outcomes.
The company’s own products, partner products and also targeted products of German competitors will be offered via the Natural Pharma sales platform.

Business partner

Become our partner and actively participate with your resources in the German cannabis market. With our in-depth understanding of the German cannabis market and our extensive experience in natural pharma, we provide you with a secure and profitable investment opportunity.

Contact:
business(ät)natpha.com
Internal forwarding: Press “Partnership” button please
Partnership

The Bundestag approves the Cannabis Act (CanG)

Berlin – Germany, 2024-02-23

Milestone in Cannabis Regulation: The Cannabis Act (CanG) has been approved

The Ampel Coalition fulfilled the promise from the November 2021 coalition agreement by passing the CanG in the Bundestag on February 23, 2024.

The bill was first discussed in the Bundestag in October of last year, and since then, several adjustments have been made to the original draft. The law, passed in the second and third readings, is set to come into effect on April 1, 2024. It will allow the use of cannabis either through personal cultivation or as part of membership in a cultivation association. The cultivation associations are expected to become active from July 1, 2024, onwards.

The changes introduced by the CanG are scheduled for initial evaluation in 2025, with further evaluations planned at specific intervals.

The passage of the CanG in the Bundestag on February 23, 2024, marks a significant milestone on the path to the legalization of cannabis in Germany. This step constitutes the first part of a two-pillar plan developed by the federal government for its legalization initiative. The second pillar of the plan will involve a temporary pilot project, establishing specialized cannabis stores for the controlled distribution of cannabis for recreational use.

However, the implementation of the legislative initiative may still face delays, depending on the further actions of the Bundesrat, which is expected to provide its position on the CanG on March 22, 2024. While the Bundesrat cannot prevent the passage of the law by the Bundestag, it may engage the mediation committee to review the law.

PR-Contact for Natural Pharma

Dr. Daniel König
+49 (0) 2173 940 95 91
press(ät)natpha.com

About Natural Pharma

Natural Pharma Resource (Natural Pharma) GmbH was founded at the beginning of 2022 and is based in Langenfeld, Germany.

The pharmaceutical and biotechnological company focuses on the import, storage, manufacturing, distribution and export of pharmaceutical products, preparations and substances, in particular medicinal products under the German Medicines Act (AMG), narcotics under the German Narcotics Act (BtMG) and cannabis for medicinal purposes as well as research and development in this field.

We are licensed pharmaceutical wholesalers according to § 52a of the German Medicines Act (AMG) and have a permit to handle narcotics according to § 3 of the Federal Institute for Drugs and Medical Devices (BtMG).

For more information, visit: Natural Pharma

Our Philosophie

The company philosophy of Natural Pharma is simple. The goal is to provide patients with high quality natural and medicinal products, especially those made from cannabis plants.
Natural Pharma Resource GmbH is committed to selecting manufacturers that take into account important patient welfare criteria in order to provide an additional therapeutic option for patients with previously unsatisfactory therapeutic outcomes.
The company’s own products, partner products and also targeted products of German competitors will be offered via the Natural Pharma sales platform.

Business partner

Become our partner and actively participate with your resources in the German cannabis market. With our in-depth understanding of the German cannabis market and our extensive experience in natural pharma, we provide you with a secure and profitable investment opportunity.

Contact:
business(ät)natpha.com
Internal forwarding: Press “Partnership” button please
Partnership

High-Terpen levels confirmed in German labs!

(© https://de.123rf.com/profile_parilovv and © mixed with company logo®)
Langenfeld (rhld.) – Germany, 2022-08-18

Today, we will focus our attention on the “entourage effect” and the important role of “terpenes” in cannabis therapy according to existing scientific research.

Short flashback: The “entourage effect” was first described by Dr. Ben-Shabat in 1998 and was explained and expanded upon in particular by Dr. Ethan Russo. Dr. Ethan Russo, M.D., a neurologist who has long studied cannabis active ingredients and their role in the body extensively, published the following study in 2011: “Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects” 

Natural Pharma‘s stance on the “entourage effect” is:

Especially in the medical field, “entourage effect” should not be disregarded. Our partner Beacon Medical Germany, a German subsidiary of the Canadian company VIVO Cannabis Inc. (TSX: VIVO) (OTCQX: VVCIF), focuses on high-quality and full transparency of the imported cannabis products to Germany. In order to achieve full transparency, we offer in addition to our COA, an up-to-date terpene analysis for each batch. This enables the treating physicians and especially the patients to provide a targeted therapy. Proverb: Entourage effect.

Therefore, we would like to share with you our achievement:

Our partner product, Beacon Indica THC 20Sensi Star (Batch 1251SI31401) has been measured and confirmed by a German testing laboratory with a terpene concentration of 2.92%.

In Germany, no one except us offers an up-to-date terpene analysis for the available batches. The reason is, in Germany it is not mandatory to provide terpene information. But with exception of THC and CBD according to the German Pharmacopoeia (DAB).

We placed great emphasis with VIVO Cannabis® and Beacon Medical Germany to provide a transparent medical cannabis product, which has allowed us to gain more and more trust from physicians and patients in Germany.

Further medical cannabis products from VIVO’s large portfolio will follow. Which Canadian products these will be, this is a secret of the companies for the time being.

But we can tell you one thing:

We will continue to introduce transparent medical cannabis products.

 

PR-Contact for Natural Pharma

Dr. Daniel König
+49 (0) 2173 940 95 91
press(ät)natpha.com

About Natural Pharma

Natural Pharma Resource (Natural Pharma) GmbH was founded at the beginning of 2022 and is based in Langenfeld, Germany.

The pharmaceutical and biotechnological company focuses on the import, storage, manufacturing, distribution and export of pharmaceutical products, preparations and substances, in particular medicinal products under the German Medicines Act (AMG), narcotics under the German Narcotics Act (BtMG) and cannabis for medicinal purposes as well as research and development in this field.

We are licensed pharmaceutical wholesalers according to § 52a of the German Medicines Act (AMG) and have a permit to handle narcotics according to § 3 of the Federal Institute for Drugs and Medical Devices (BtMG).

 

For more information, visit: Natural Pharma

Our Philosophie

The company philosophy of Natural Pharma is simple. The goal is to provide patients with high quality natural and medicinal products, especially those made from cannabis plants.
Natural Pharma Resource GmbH is committed to selecting manufacturers that take into account important patient welfare criteria in order to provide an additional therapeutic option for patients with previously unsatisfactory therapeutic outcomes.
The company’s own products, partner products and also targeted products of German competitors will be offered via the Natural Pharma sales platform.

About VIVO Cannabis

VIVO Cannabis® is recognized for trusted, premium cannabis products and services. Through its Canna Farms and ABcann business units, VIVO holds production and sales licences from Health Canada and operates world-class indoor cultivation facilities. VIVO has a collection of premium brands, each targeting different customer segments, including Canna Farms™, Beacon Medical®, Fireside™, and Lumina™. Harvest Medicine™, VIVO’s patient-centric, scalable network of medical cannabis clinics, has serviced over 200,000 patient visits. VIVO is pursuing several partnership and product development opportunities and is focusing its international efforts on Germany and Australia.
For more information, visit: VIVO Cannabis Inc. and Beacon Medical Germany.

Business partner

Become a partner of us and participate proactively with your resources in the supply chain of the German market for medical and recreational cannabis. As partner and company we can offer security, continuity, transparency and trust.


Contact:
business(ät)natpha.com
Internal forwarding: Press “Business” button please
Business

Welcome to Natural Pharma!

(© Natural Pharma Resource GmbH – Logo)
Langenfeld (rhld.) – Germany, 2022-08-09

Welcome to Natural Pharma! The former founding member and CEO of Medical Pharma Resource GmbH, Mr. Engin Ates, has moved on after 4 years in August 2022 to start a new challenge with Natural Pharma. The new pharmaceutical and biotechnology company will start the distribution to German pharmacies in a timely manner.

An exclusive partnership with Beacon Medical Germany GmbH, a German subsidiary of the Canadian VIVO Cannabis Inc., has been re-established.

PR-Contact for Natural Pharma

Dr. Daniel König
+49 (0) 2173 940 95 91
press(ät)natpha.com

About Natural Pharma

Natural Pharma Resource (Natural Pharma) GmbH was founded at the beginning of 2022 and is based in Langenfeld, Germany. The pharmaceutical and biotechnological company focuses on the import, storage, manufacturing, distribution and export of pharmaceutical products, preparations and substances, in particular medicinal products under the German Medicines Act (AMG), narcotics under the German Narcotics Act (BtMG) and cannabis for medicinal purposes as well as research and development in this field.


We are licensed pharmaceutical wholesalers according to § 52a of the German Medicines Act (AMG) and have a permit to handle narcotics according to § 3 of the Federal Institute for Drugs and Medical Devices (BtMG).

Our Philosophie

The company philosophy of Natural Pharma is simple. The goal is to provide patients with high quality natural and medicinal products, especially those made from cannabis plants.
Natural Pharma Resource GmbH is committed to selecting manufacturers that take into account important patient welfare criteria in order to provide an additional therapeutic option for patients with previously unsatisfactory therapeutic outcomes.
The company’s own products, partner products and also targeted products of German competitors will be offered via the Natural Pharma sales platform.
For more information, visit: Natural Pharma

About VIVO Cannabis

VIVO Cannabis® is recognized for trusted, premium cannabis products and services. Through its Canna Farms and ABcann business units, VIVO holds production and sales licences from Health Canada and operates world-class indoor cultivation facilities. VIVO has a collection of premium brands, each targeting different customer segments, including Canna Farms™, Beacon Medical®, Fireside™, and Lumina™. Harvest Medicine™, VIVO’s patient-centric, scalable network of medical cannabis clinics, has serviced over 200,000 patient visits. VIVO is pursuing several partnership and product development opportunities and is focusing its international efforts on Germany and Australia.
For more information, visit: VIVO Cannabis Inc. and Beacon Medical Germany.

Business partner

Become a partner of us and participate proactively with your resources in the supply chain of the German market for medical and recreational cannabis. As partner and company we can offer security, continuity, transparency and trust.


Contact:
business(ät)natpha.com
Internal forwarding: Press “Business” button please
Business